Global Dermatomycoses Drug Supply, Demand and Key Producers, 2026-2032
The global Dermatomycoses Drug market size is expected to reach $ 19734 million by 2032, rising at a market growth of 3.6% CAGR during the forecast period (2026-2032).
Dermatomycoses Drug refers to a general category of pharmaceutical products used for the treatment of superficial mycoses caused by filamentous fungal infections such as dermatophytes. Dermatomycoses are fungal infections of the stratum corneum, hair, and nail plates, primarily caused by three major genera of dermatophytes: Trichophyton, Microsporum, and Epidermophyton, with clinical manifestations including tinea corporis, tinea cruris, tinea pedis, and onychomycosis. An estimated 20 to 25 percent of the global population is affected by dermatomycoses, making it the most prevalent type of fungal infection worldwide. Unlike traditional antifungal drugs, modern Dermatomycoses Drugs exert therapeutic effects through mechanisms including inhibition of ergosterol biosynthesis or disruption of fungal cell membrane integrity. From an industrial attribute perspective, Dermatomycoses Drugs sit at the intersection of antifungal drug discovery, dermatology therapeutics, and pharmaceutical formulation technology, encompassing two major categories: topical preparations and systemic oral formulations. Their core value lies in improving patient quality of life through targeted therapy, shortening treatment duration, reducing recurrence rates, while addressing the growing challenge of antifungal resistance. The US Centers for Disease Control and Prevention notes that only three classes of antifungal drugs are available, and resistant fungal infections have become a major global public health challenge.
Market Development Opportunities and Main Drivers
Accelerating global population aging and the expanding population of immunocompromised individuals directly drive clinical demand for Dermatomycoses Drugs. The WHO Fungal Priority Pathogens List provides clear policy direction for antifungal drug development. Novel antifungal compounds such as olorofim and ME1111 represent a new drug class targeting intracellular metabolism, while nanotechnology platforms demonstrate significant potential in enhancing the bioavailability and safety of existing drugs. Innovative strategies including vaccine development and antimicrobial peptides are entering clinical research stages. The expert consensus guidelines issued by the Indian Association of Dermatologists, Venereologists and Leprologists provide standardized treatment protocols for the management of complicated and refractory dermatophytosis.
Market Challenges and Risks
Only three classes of antifungal drugs are available, while some dermatophytes such as Trichophyton indotineae have shown extensive resistance to first line agents including terbinafine. The widespread use of fungicides in agriculture and horticulture presents a risk of cross resistance with medical antifungal drugs, as environmental Aspergillus exposed to agricultural fungicides can develop resistance. Long product development cycles and high regulatory barriers represent another major challenge, with novel antifungal drugs typically requiring more than a decade from discovery to market. The supply concentration and price volatility of active pharmaceutical ingredients affect production cost stability, while the hepatotoxicity risk of certain oral antifungal drugs limits their use in specific patient populations.
Downstream Demand Trends
The onychomycosis treatment field shows continued growth in demand for long term oral therapeutic regimens, with patient expectations for shorter treatment duration and improved cure rates driving clinical adoption of novel drugs. In the treatment of tinea corporis and tinea cruris, topical antifungals remain the mainstream choice, but treatment needs for drug resistant strain infections are driving increased prescribing of oral medications. The high incidence of tinea capitis in pediatric populations drives stable demand for oral antifungal drugs. Immunocompromised patient populations including organ transplant recipients, HIV infected individuals, and diabetes patients show significantly higher demand for both prophylactic and therapeutic antifungal drugs compared to the general population.
Regional Trends
The North American market, with its comprehensive healthcare system and high antifungal drug accessibility, leads in the commercialization of innovative drugs, with antifungal stewardship programs promoted by the US Centers for Disease Control and Prevention optimizing prescribing practices. The European market, influenced by deepening aging demographics and mature resistance surveillance systems, shows continued growth in demand for novel antifungal drugs. The Asia Pacific region, particularly India, with its high prevalence of dermatomycoses and circulation of resistant strains, has become a key region for clinical research and market expansion of novel drugs, where expert consensus guidelines issued by the Indian Association of Dermatologists, Venereologists and Leprologists have provided a framework for standardized treatment.
This report studies the global Dermatomycoses Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Dermatomycoses Drug and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Dermatomycoses Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Dermatomycoses Drug total production and demand, 2021-2032, (K Dose)
Global Dermatomycoses Drug total production value, 2021-2032, (USD Million)
Global Dermatomycoses Drug production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Dermatomycoses Drug consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Dermatomycoses Drug domestic production, consumption, key domestic manufacturers and share
Global Dermatomycoses Drug production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Dermatomycoses Drug production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Dermatomycoses Drug production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Dermatomycoses Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Biolab Farmaceutica, Blueberry Therapeutics, Daewoong Pharmaceutical, Dermala, Helix BioMedix, Pelthos, Sol-Gel Technologies, Vyome, Perrigo, Almirall, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Dermatomycoses Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Dermatomycoses Drug Market, By Region:
1. How big is the global Dermatomycoses Drug market?
2. What is the demand of the global Dermatomycoses Drug market?
3. What is the year over year growth of the global Dermatomycoses Drug market?
4. What is the production and production value of the global Dermatomycoses Drug market?
5. Who are the key producers in the global Dermatomycoses Drug market?
6. What are the growth factors driving the market demand?
Dermatomycoses Drug refers to a general category of pharmaceutical products used for the treatment of superficial mycoses caused by filamentous fungal infections such as dermatophytes. Dermatomycoses are fungal infections of the stratum corneum, hair, and nail plates, primarily caused by three major genera of dermatophytes: Trichophyton, Microsporum, and Epidermophyton, with clinical manifestations including tinea corporis, tinea cruris, tinea pedis, and onychomycosis. An estimated 20 to 25 percent of the global population is affected by dermatomycoses, making it the most prevalent type of fungal infection worldwide. Unlike traditional antifungal drugs, modern Dermatomycoses Drugs exert therapeutic effects through mechanisms including inhibition of ergosterol biosynthesis or disruption of fungal cell membrane integrity. From an industrial attribute perspective, Dermatomycoses Drugs sit at the intersection of antifungal drug discovery, dermatology therapeutics, and pharmaceutical formulation technology, encompassing two major categories: topical preparations and systemic oral formulations. Their core value lies in improving patient quality of life through targeted therapy, shortening treatment duration, reducing recurrence rates, while addressing the growing challenge of antifungal resistance. The US Centers for Disease Control and Prevention notes that only three classes of antifungal drugs are available, and resistant fungal infections have become a major global public health challenge.
Market Development Opportunities and Main Drivers
Accelerating global population aging and the expanding population of immunocompromised individuals directly drive clinical demand for Dermatomycoses Drugs. The WHO Fungal Priority Pathogens List provides clear policy direction for antifungal drug development. Novel antifungal compounds such as olorofim and ME1111 represent a new drug class targeting intracellular metabolism, while nanotechnology platforms demonstrate significant potential in enhancing the bioavailability and safety of existing drugs. Innovative strategies including vaccine development and antimicrobial peptides are entering clinical research stages. The expert consensus guidelines issued by the Indian Association of Dermatologists, Venereologists and Leprologists provide standardized treatment protocols for the management of complicated and refractory dermatophytosis.
Market Challenges and Risks
Only three classes of antifungal drugs are available, while some dermatophytes such as Trichophyton indotineae have shown extensive resistance to first line agents including terbinafine. The widespread use of fungicides in agriculture and horticulture presents a risk of cross resistance with medical antifungal drugs, as environmental Aspergillus exposed to agricultural fungicides can develop resistance. Long product development cycles and high regulatory barriers represent another major challenge, with novel antifungal drugs typically requiring more than a decade from discovery to market. The supply concentration and price volatility of active pharmaceutical ingredients affect production cost stability, while the hepatotoxicity risk of certain oral antifungal drugs limits their use in specific patient populations.
Downstream Demand Trends
The onychomycosis treatment field shows continued growth in demand for long term oral therapeutic regimens, with patient expectations for shorter treatment duration and improved cure rates driving clinical adoption of novel drugs. In the treatment of tinea corporis and tinea cruris, topical antifungals remain the mainstream choice, but treatment needs for drug resistant strain infections are driving increased prescribing of oral medications. The high incidence of tinea capitis in pediatric populations drives stable demand for oral antifungal drugs. Immunocompromised patient populations including organ transplant recipients, HIV infected individuals, and diabetes patients show significantly higher demand for both prophylactic and therapeutic antifungal drugs compared to the general population.
Regional Trends
The North American market, with its comprehensive healthcare system and high antifungal drug accessibility, leads in the commercialization of innovative drugs, with antifungal stewardship programs promoted by the US Centers for Disease Control and Prevention optimizing prescribing practices. The European market, influenced by deepening aging demographics and mature resistance surveillance systems, shows continued growth in demand for novel antifungal drugs. The Asia Pacific region, particularly India, with its high prevalence of dermatomycoses and circulation of resistant strains, has become a key region for clinical research and market expansion of novel drugs, where expert consensus guidelines issued by the Indian Association of Dermatologists, Venereologists and Leprologists have provided a framework for standardized treatment.
This report studies the global Dermatomycoses Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Dermatomycoses Drug and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Dermatomycoses Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Dermatomycoses Drug total production and demand, 2021-2032, (K Dose)
Global Dermatomycoses Drug total production value, 2021-2032, (USD Million)
Global Dermatomycoses Drug production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Dermatomycoses Drug consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Dermatomycoses Drug domestic production, consumption, key domestic manufacturers and share
Global Dermatomycoses Drug production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Dermatomycoses Drug production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Dermatomycoses Drug production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Dermatomycoses Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Biolab Farmaceutica, Blueberry Therapeutics, Daewoong Pharmaceutical, Dermala, Helix BioMedix, Pelthos, Sol-Gel Technologies, Vyome, Perrigo, Almirall, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Dermatomycoses Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Dermatomycoses Drug Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Topical Drug
- Oral Drug
- Cream
- Solution
- Lacquer
- Powder
- Tablet
- Ergosterol Synthesis Inhibitor
- Cell Membrane Disruptor
- Keratinization Promoter
- Hospital
- Retail Pharmacy
- Online Pharmacy
- Biolab Farmaceutica
- Blueberry Therapeutics
- Daewoong Pharmaceutical
- Dermala
- Helix BioMedix
- Pelthos
- Sol-Gel Technologies
- Vyome
- Perrigo
- Almirall
- Advacare Pharma
- Resources Sanjiu
- Xiuzheng
1. How big is the global Dermatomycoses Drug market?
2. What is the demand of the global Dermatomycoses Drug market?
3. What is the year over year growth of the global Dermatomycoses Drug market?
4. What is the production and production value of the global Dermatomycoses Drug market?
5. Who are the key producers in the global Dermatomycoses Drug market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Dermatomycoses Drug Introduction
1.2 World Dermatomycoses Drug Supply & Forecast
1.2.1 World Dermatomycoses Drug Production Value (2021 & 2025 & 2032)
1.2.2 World Dermatomycoses Drug Production (2021-2032)
1.2.3 World Dermatomycoses Drug Pricing Trends (2021-2032)
1.3 World Dermatomycoses Drug Production by Region (Based on Production Site)
1.3.1 World Dermatomycoses Drug Production Value by Region (2021-2032)
1.3.2 World Dermatomycoses Drug Production by Region (2021-2032)
1.3.3 World Dermatomycoses Drug Average Price by Region (2021-2032)
1.3.4 North America Dermatomycoses Drug Production (2021-2032)
1.3.5 Europe Dermatomycoses Drug Production (2021-2032)
1.3.6 Asia Dermatomycoses Drug Production (2021-2032)
1.3.7 Latin America Dermatomycoses Drug Production (2021-2032)
1.3.8 Middle East Dermatomycoses Drug Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Dermatomycoses Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Dermatomycoses Drug Major Market Trends
2 DEMAND SUMMARY
2.1 World Dermatomycoses Drug Demand (2021-2032)
2.2 World Dermatomycoses Drug Consumption by Region
2.2.1 World Dermatomycoses Drug Consumption by Region (2021-2026)
2.2.2 World Dermatomycoses Drug Consumption Forecast by Region (2027-2032)
2.3 United States Dermatomycoses Drug Consumption (2021-2032)
2.4 China Dermatomycoses Drug Consumption (2021-2032)
2.5 Europe Dermatomycoses Drug Consumption (2021-2032)
2.6 Japan Dermatomycoses Drug Consumption (2021-2032)
2.7 South Korea Dermatomycoses Drug Consumption (2021-2032)
2.8 ASEAN Dermatomycoses Drug Consumption (2021-2032)
2.9 India Dermatomycoses Drug Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Dermatomycoses Drug Production Value by Manufacturer (2021-2026)
3.2 World Dermatomycoses Drug Production by Manufacturer (2021-2026)
3.3 World Dermatomycoses Drug Average Price by Manufacturer (2021-2026)
3.4 Dermatomycoses Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Dermatomycoses Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Dermatomycoses Drug in 2025
3.5.3 Global Concentration Ratios (CR8) for Dermatomycoses Drug in 2025
3.6 Dermatomycoses Drug Market: Overall Company Footprint Analysis
3.6.1 Dermatomycoses Drug Market: Region Footprint
3.6.2 Dermatomycoses Drug Market: Company Product Type Footprint
3.6.3 Dermatomycoses Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Dermatomycoses Drug Production Value Comparison
4.1.1 United States VS China: Dermatomycoses Drug Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Dermatomycoses Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Dermatomycoses Drug Production Comparison
4.2.1 United States VS China: Dermatomycoses Drug Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Dermatomycoses Drug Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Dermatomycoses Drug Consumption Comparison
4.3.1 United States VS China: Dermatomycoses Drug Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Dermatomycoses Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Dermatomycoses Drug Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Dermatomycoses Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Dermatomycoses Drug Production Value (2021-2026)
4.4.3 United States Based Manufacturers Dermatomycoses Drug Production (2021-2026)
4.5 China Based Dermatomycoses Drug Manufacturers and Market Share
4.5.1 China Based Dermatomycoses Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Dermatomycoses Drug Production Value (2021-2026)
4.5.3 China Based Manufacturers Dermatomycoses Drug Production (2021-2026)
4.6 Rest of World Based Dermatomycoses Drug Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Dermatomycoses Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Dermatomycoses Drug Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Dermatomycoses Drug Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Dermatomycoses Drug Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Topical Drug
5.2.2 Oral Drug
5.3 Market Segment by Type
5.3.1 World Dermatomycoses Drug Production by Type (2021-2032)
5.3.2 World Dermatomycoses Drug Production Value by Type (2021-2032)
5.3.3 World Dermatomycoses Drug Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY DOSAGE FORM
6.1 World Dermatomycoses Drug Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Dosage Form
6.2.1 Cream
6.2.2 Solution
6.2.3 Lacquer
6.2.4 Powder
6.2.5 Tablet
6.3 Market Segment by Dosage Form
6.3.1 World Dermatomycoses Drug Production by Dosage Form (2021-2032)
6.3.2 World Dermatomycoses Drug Production Value by Dosage Form (2021-2032)
6.3.3 World Dermatomycoses Drug Average Price by Dosage Form (2021-2032)
7 MARKET ANALYSIS BY MECHANISM
7.1 World Dermatomycoses Drug Market Size Overview by Mechanism: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Mechanism
7.2.1 Ergosterol Synthesis Inhibitor
7.2.2 Cell Membrane Disruptor
7.2.3 Keratinization Promoter
7.3 Market Segment by Mechanism
7.3.1 World Dermatomycoses Drug Production by Mechanism (2021-2032)
7.3.2 World Dermatomycoses Drug Production Value by Mechanism (2021-2032)
7.3.3 World Dermatomycoses Drug Average Price by Mechanism (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Dermatomycoses Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Retail Pharmacy
8.2.3 Online Pharmacy
8.3 Market Segment by Application
8.3.1 World Dermatomycoses Drug Production by Application (2021-2032)
8.3.2 World Dermatomycoses Drug Production Value by Application (2021-2032)
8.3.3 World Dermatomycoses Drug Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Biolab Farmaceutica
9.1.1 Biolab Farmaceutica Details
9.1.2 Biolab Farmaceutica Major Business
9.1.3 Biolab Farmaceutica Dermatomycoses Drug Product and Services
9.1.4 Biolab Farmaceutica Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Biolab Farmaceutica Recent Developments/Updates
9.1.6 Biolab Farmaceutica Competitive Strengths & Weaknesses
9.2 Blueberry Therapeutics
9.2.1 Blueberry Therapeutics Details
9.2.2 Blueberry Therapeutics Major Business
9.2.3 Blueberry Therapeutics Dermatomycoses Drug Product and Services
9.2.4 Blueberry Therapeutics Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Blueberry Therapeutics Recent Developments/Updates
9.2.6 Blueberry Therapeutics Competitive Strengths & Weaknesses
9.3 Daewoong Pharmaceutical
9.3.1 Daewoong Pharmaceutical Details
9.3.2 Daewoong Pharmaceutical Major Business
9.3.3 Daewoong Pharmaceutical Dermatomycoses Drug Product and Services
9.3.4 Daewoong Pharmaceutical Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Daewoong Pharmaceutical Recent Developments/Updates
9.3.6 Daewoong Pharmaceutical Competitive Strengths & Weaknesses
9.4 Dermala
9.4.1 Dermala Details
9.4.2 Dermala Major Business
9.4.3 Dermala Dermatomycoses Drug Product and Services
9.4.4 Dermala Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Dermala Recent Developments/Updates
9.4.6 Dermala Competitive Strengths & Weaknesses
9.5 Helix BioMedix
9.5.1 Helix BioMedix Details
9.5.2 Helix BioMedix Major Business
9.5.3 Helix BioMedix Dermatomycoses Drug Product and Services
9.5.4 Helix BioMedix Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Helix BioMedix Recent Developments/Updates
9.5.6 Helix BioMedix Competitive Strengths & Weaknesses
9.6 Pelthos
9.6.1 Pelthos Details
9.6.2 Pelthos Major Business
9.6.3 Pelthos Dermatomycoses Drug Product and Services
9.6.4 Pelthos Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Pelthos Recent Developments/Updates
9.6.6 Pelthos Competitive Strengths & Weaknesses
9.7 Sol-Gel Technologies
9.7.1 Sol-Gel Technologies Details
9.7.2 Sol-Gel Technologies Major Business
9.7.3 Sol-Gel Technologies Dermatomycoses Drug Product and Services
9.7.4 Sol-Gel Technologies Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Sol-Gel Technologies Recent Developments/Updates
9.7.6 Sol-Gel Technologies Competitive Strengths & Weaknesses
9.8 Vyome
9.8.1 Vyome Details
9.8.2 Vyome Major Business
9.8.3 Vyome Dermatomycoses Drug Product and Services
9.8.4 Vyome Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Vyome Recent Developments/Updates
9.8.6 Vyome Competitive Strengths & Weaknesses
9.9 Perrigo
9.9.1 Perrigo Details
9.9.2 Perrigo Major Business
9.9.3 Perrigo Dermatomycoses Drug Product and Services
9.9.4 Perrigo Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Perrigo Recent Developments/Updates
9.9.6 Perrigo Competitive Strengths & Weaknesses
9.10 Almirall
9.10.1 Almirall Details
9.10.2 Almirall Major Business
9.10.3 Almirall Dermatomycoses Drug Product and Services
9.10.4 Almirall Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Almirall Recent Developments/Updates
9.10.6 Almirall Competitive Strengths & Weaknesses
9.11 Advacare Pharma
9.11.1 Advacare Pharma Details
9.11.2 Advacare Pharma Major Business
9.11.3 Advacare Pharma Dermatomycoses Drug Product and Services
9.11.4 Advacare Pharma Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Advacare Pharma Recent Developments/Updates
9.11.6 Advacare Pharma Competitive Strengths & Weaknesses
9.12 Resources Sanjiu
9.12.1 Resources Sanjiu Details
9.12.2 Resources Sanjiu Major Business
9.12.3 Resources Sanjiu Dermatomycoses Drug Product and Services
9.12.4 Resources Sanjiu Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Resources Sanjiu Recent Developments/Updates
9.12.6 Resources Sanjiu Competitive Strengths & Weaknesses
9.13 Xiuzheng
9.13.1 Xiuzheng Details
9.13.2 Xiuzheng Major Business
9.13.3 Xiuzheng Dermatomycoses Drug Product and Services
9.13.4 Xiuzheng Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Xiuzheng Recent Developments/Updates
9.13.6 Xiuzheng Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Dermatomycoses Drug Industry Chain
10.2 Dermatomycoses Drug Upstream Analysis
10.2.1 Dermatomycoses Drug Core Raw Materials
10.2.2 Main Manufacturers of Dermatomycoses Drug Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Dermatomycoses Drug Production Mode
10.6 Dermatomycoses Drug Procurement Model
10.7 Dermatomycoses Drug Industry Sales Model and Sales Channels
10.7.1 Dermatomycoses Drug Sales Model
10.7.2 Dermatomycoses Drug Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Dermatomycoses Drug Introduction
1.2 World Dermatomycoses Drug Supply & Forecast
1.2.1 World Dermatomycoses Drug Production Value (2021 & 2025 & 2032)
1.2.2 World Dermatomycoses Drug Production (2021-2032)
1.2.3 World Dermatomycoses Drug Pricing Trends (2021-2032)
1.3 World Dermatomycoses Drug Production by Region (Based on Production Site)
1.3.1 World Dermatomycoses Drug Production Value by Region (2021-2032)
1.3.2 World Dermatomycoses Drug Production by Region (2021-2032)
1.3.3 World Dermatomycoses Drug Average Price by Region (2021-2032)
1.3.4 North America Dermatomycoses Drug Production (2021-2032)
1.3.5 Europe Dermatomycoses Drug Production (2021-2032)
1.3.6 Asia Dermatomycoses Drug Production (2021-2032)
1.3.7 Latin America Dermatomycoses Drug Production (2021-2032)
1.3.8 Middle East Dermatomycoses Drug Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Dermatomycoses Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Dermatomycoses Drug Major Market Trends
2 DEMAND SUMMARY
2.1 World Dermatomycoses Drug Demand (2021-2032)
2.2 World Dermatomycoses Drug Consumption by Region
2.2.1 World Dermatomycoses Drug Consumption by Region (2021-2026)
2.2.2 World Dermatomycoses Drug Consumption Forecast by Region (2027-2032)
2.3 United States Dermatomycoses Drug Consumption (2021-2032)
2.4 China Dermatomycoses Drug Consumption (2021-2032)
2.5 Europe Dermatomycoses Drug Consumption (2021-2032)
2.6 Japan Dermatomycoses Drug Consumption (2021-2032)
2.7 South Korea Dermatomycoses Drug Consumption (2021-2032)
2.8 ASEAN Dermatomycoses Drug Consumption (2021-2032)
2.9 India Dermatomycoses Drug Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Dermatomycoses Drug Production Value by Manufacturer (2021-2026)
3.2 World Dermatomycoses Drug Production by Manufacturer (2021-2026)
3.3 World Dermatomycoses Drug Average Price by Manufacturer (2021-2026)
3.4 Dermatomycoses Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Dermatomycoses Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Dermatomycoses Drug in 2025
3.5.3 Global Concentration Ratios (CR8) for Dermatomycoses Drug in 2025
3.6 Dermatomycoses Drug Market: Overall Company Footprint Analysis
3.6.1 Dermatomycoses Drug Market: Region Footprint
3.6.2 Dermatomycoses Drug Market: Company Product Type Footprint
3.6.3 Dermatomycoses Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Dermatomycoses Drug Production Value Comparison
4.1.1 United States VS China: Dermatomycoses Drug Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Dermatomycoses Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Dermatomycoses Drug Production Comparison
4.2.1 United States VS China: Dermatomycoses Drug Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Dermatomycoses Drug Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Dermatomycoses Drug Consumption Comparison
4.3.1 United States VS China: Dermatomycoses Drug Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Dermatomycoses Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Dermatomycoses Drug Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Dermatomycoses Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Dermatomycoses Drug Production Value (2021-2026)
4.4.3 United States Based Manufacturers Dermatomycoses Drug Production (2021-2026)
4.5 China Based Dermatomycoses Drug Manufacturers and Market Share
4.5.1 China Based Dermatomycoses Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Dermatomycoses Drug Production Value (2021-2026)
4.5.3 China Based Manufacturers Dermatomycoses Drug Production (2021-2026)
4.6 Rest of World Based Dermatomycoses Drug Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Dermatomycoses Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Dermatomycoses Drug Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Dermatomycoses Drug Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Dermatomycoses Drug Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Topical Drug
5.2.2 Oral Drug
5.3 Market Segment by Type
5.3.1 World Dermatomycoses Drug Production by Type (2021-2032)
5.3.2 World Dermatomycoses Drug Production Value by Type (2021-2032)
5.3.3 World Dermatomycoses Drug Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY DOSAGE FORM
6.1 World Dermatomycoses Drug Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Dosage Form
6.2.1 Cream
6.2.2 Solution
6.2.3 Lacquer
6.2.4 Powder
6.2.5 Tablet
6.3 Market Segment by Dosage Form
6.3.1 World Dermatomycoses Drug Production by Dosage Form (2021-2032)
6.3.2 World Dermatomycoses Drug Production Value by Dosage Form (2021-2032)
6.3.3 World Dermatomycoses Drug Average Price by Dosage Form (2021-2032)
7 MARKET ANALYSIS BY MECHANISM
7.1 World Dermatomycoses Drug Market Size Overview by Mechanism: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Mechanism
7.2.1 Ergosterol Synthesis Inhibitor
7.2.2 Cell Membrane Disruptor
7.2.3 Keratinization Promoter
7.3 Market Segment by Mechanism
7.3.1 World Dermatomycoses Drug Production by Mechanism (2021-2032)
7.3.2 World Dermatomycoses Drug Production Value by Mechanism (2021-2032)
7.3.3 World Dermatomycoses Drug Average Price by Mechanism (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Dermatomycoses Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Retail Pharmacy
8.2.3 Online Pharmacy
8.3 Market Segment by Application
8.3.1 World Dermatomycoses Drug Production by Application (2021-2032)
8.3.2 World Dermatomycoses Drug Production Value by Application (2021-2032)
8.3.3 World Dermatomycoses Drug Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Biolab Farmaceutica
9.1.1 Biolab Farmaceutica Details
9.1.2 Biolab Farmaceutica Major Business
9.1.3 Biolab Farmaceutica Dermatomycoses Drug Product and Services
9.1.4 Biolab Farmaceutica Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Biolab Farmaceutica Recent Developments/Updates
9.1.6 Biolab Farmaceutica Competitive Strengths & Weaknesses
9.2 Blueberry Therapeutics
9.2.1 Blueberry Therapeutics Details
9.2.2 Blueberry Therapeutics Major Business
9.2.3 Blueberry Therapeutics Dermatomycoses Drug Product and Services
9.2.4 Blueberry Therapeutics Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Blueberry Therapeutics Recent Developments/Updates
9.2.6 Blueberry Therapeutics Competitive Strengths & Weaknesses
9.3 Daewoong Pharmaceutical
9.3.1 Daewoong Pharmaceutical Details
9.3.2 Daewoong Pharmaceutical Major Business
9.3.3 Daewoong Pharmaceutical Dermatomycoses Drug Product and Services
9.3.4 Daewoong Pharmaceutical Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Daewoong Pharmaceutical Recent Developments/Updates
9.3.6 Daewoong Pharmaceutical Competitive Strengths & Weaknesses
9.4 Dermala
9.4.1 Dermala Details
9.4.2 Dermala Major Business
9.4.3 Dermala Dermatomycoses Drug Product and Services
9.4.4 Dermala Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Dermala Recent Developments/Updates
9.4.6 Dermala Competitive Strengths & Weaknesses
9.5 Helix BioMedix
9.5.1 Helix BioMedix Details
9.5.2 Helix BioMedix Major Business
9.5.3 Helix BioMedix Dermatomycoses Drug Product and Services
9.5.4 Helix BioMedix Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Helix BioMedix Recent Developments/Updates
9.5.6 Helix BioMedix Competitive Strengths & Weaknesses
9.6 Pelthos
9.6.1 Pelthos Details
9.6.2 Pelthos Major Business
9.6.3 Pelthos Dermatomycoses Drug Product and Services
9.6.4 Pelthos Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Pelthos Recent Developments/Updates
9.6.6 Pelthos Competitive Strengths & Weaknesses
9.7 Sol-Gel Technologies
9.7.1 Sol-Gel Technologies Details
9.7.2 Sol-Gel Technologies Major Business
9.7.3 Sol-Gel Technologies Dermatomycoses Drug Product and Services
9.7.4 Sol-Gel Technologies Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Sol-Gel Technologies Recent Developments/Updates
9.7.6 Sol-Gel Technologies Competitive Strengths & Weaknesses
9.8 Vyome
9.8.1 Vyome Details
9.8.2 Vyome Major Business
9.8.3 Vyome Dermatomycoses Drug Product and Services
9.8.4 Vyome Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Vyome Recent Developments/Updates
9.8.6 Vyome Competitive Strengths & Weaknesses
9.9 Perrigo
9.9.1 Perrigo Details
9.9.2 Perrigo Major Business
9.9.3 Perrigo Dermatomycoses Drug Product and Services
9.9.4 Perrigo Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Perrigo Recent Developments/Updates
9.9.6 Perrigo Competitive Strengths & Weaknesses
9.10 Almirall
9.10.1 Almirall Details
9.10.2 Almirall Major Business
9.10.3 Almirall Dermatomycoses Drug Product and Services
9.10.4 Almirall Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Almirall Recent Developments/Updates
9.10.6 Almirall Competitive Strengths & Weaknesses
9.11 Advacare Pharma
9.11.1 Advacare Pharma Details
9.11.2 Advacare Pharma Major Business
9.11.3 Advacare Pharma Dermatomycoses Drug Product and Services
9.11.4 Advacare Pharma Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Advacare Pharma Recent Developments/Updates
9.11.6 Advacare Pharma Competitive Strengths & Weaknesses
9.12 Resources Sanjiu
9.12.1 Resources Sanjiu Details
9.12.2 Resources Sanjiu Major Business
9.12.3 Resources Sanjiu Dermatomycoses Drug Product and Services
9.12.4 Resources Sanjiu Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Resources Sanjiu Recent Developments/Updates
9.12.6 Resources Sanjiu Competitive Strengths & Weaknesses
9.13 Xiuzheng
9.13.1 Xiuzheng Details
9.13.2 Xiuzheng Major Business
9.13.3 Xiuzheng Dermatomycoses Drug Product and Services
9.13.4 Xiuzheng Dermatomycoses Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Xiuzheng Recent Developments/Updates
9.13.6 Xiuzheng Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Dermatomycoses Drug Industry Chain
10.2 Dermatomycoses Drug Upstream Analysis
10.2.1 Dermatomycoses Drug Core Raw Materials
10.2.2 Main Manufacturers of Dermatomycoses Drug Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Dermatomycoses Drug Production Mode
10.6 Dermatomycoses Drug Procurement Model
10.7 Dermatomycoses Drug Industry Sales Model and Sales Channels
10.7.1 Dermatomycoses Drug Sales Model
10.7.2 Dermatomycoses Drug Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Dermatomycoses Drug Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Dermatomycoses Drug Production Value by Region (2021-2026) & (USD Million)
Table 3. World Dermatomycoses Drug Production Value by Region (2027-2032) & (USD Million)
Table 4. World Dermatomycoses Drug Production Value Market Share by Region (2021-2026)
Table 5. World Dermatomycoses Drug Production Value Market Share by Region (2027-2032)
Table 6. World Dermatomycoses Drug Production by Region (2021-2026) & (K Dose)
Table 7. World Dermatomycoses Drug Production by Region (2027-2032) & (K Dose)
Table 8. World Dermatomycoses Drug Production Market Share by Region (2021-2026)
Table 9. World Dermatomycoses Drug Production Market Share by Region (2027-2032)
Table 10. World Dermatomycoses Drug Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Dermatomycoses Drug Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Dermatomycoses Drug Major Market Trends
Table 13. World Dermatomycoses Drug Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Dermatomycoses Drug Consumption by Region (2021-2026) & (K Dose)
Table 15. World Dermatomycoses Drug Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Dermatomycoses Drug Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Dermatomycoses Drug Producers in 2025
Table 18. World Dermatomycoses Drug Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Dermatomycoses Drug Producers in 2025
Table 20. World Dermatomycoses Drug Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Dermatomycoses Drug Company Evaluation Quadrant
Table 22. World Dermatomycoses Drug Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Dermatomycoses Drug Production Site of Key Manufacturer
Table 24. Dermatomycoses Drug Market: Company Product Type Footprint
Table 25. Dermatomycoses Drug Market: Company Product Application Footprint
Table 26. Dermatomycoses Drug Competitive Factors
Table 27. Dermatomycoses Drug New Entrant and Capacity Expansion Plans
Table 28. Dermatomycoses Drug Mergers & Acquisitions Activity
Table 29. United States VS China Dermatomycoses Drug Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Dermatomycoses Drug Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Dermatomycoses Drug Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Dermatomycoses Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Dermatomycoses Drug Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Dermatomycoses Drug Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Dermatomycoses Drug Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Dermatomycoses Drug Production Market Share (2021-2026)
Table 37. China Based Dermatomycoses Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Dermatomycoses Drug Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Dermatomycoses Drug Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Dermatomycoses Drug Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Dermatomycoses Drug Production Market Share (2021-2026)
Table 42. Rest of World Based Dermatomycoses Drug Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Dermatomycoses Drug Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Dermatomycoses Drug Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Dermatomycoses Drug Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Dermatomycoses Drug Production Market Share (2021-2026)
Table 47. World Dermatomycoses Drug Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Dermatomycoses Drug Production by Type (2021-2026) & (K Dose)
Table 49. World Dermatomycoses Drug Production by Type (2027-2032) & (K Dose)
Table 50. World Dermatomycoses Drug Production Value by Type (2021-2026) & (USD Million)
Table 51. World Dermatomycoses Drug Production Value by Type (2027-2032) & (USD Million)
Table 52. World Dermatomycoses Drug Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Dermatomycoses Drug Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Dermatomycoses Drug Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 55. World Dermatomycoses Drug Production by Dosage Form (2021-2026) & (K Dose)
Table 56. World Dermatomycoses Drug Production by Dosage Form (2027-2032) & (K Dose)
Table 57. World Dermatomycoses Drug Production Value by Dosage Form (2021-2026) & (USD Million)
Table 58. World Dermatomycoses Drug Production Value by Dosage Form (2027-2032) & (USD Million)
Table 59. World Dermatomycoses Drug Average Price by Dosage Form (2021-2026) & (US$/Dose)
Table 60. World Dermatomycoses Drug Average Price by Dosage Form (2027-2032) & (US$/Dose)
Table 61. World Dermatomycoses Drug Production Value by Mechanism, (USD Million), 2021 & 2025 & 2032
Table 62. World Dermatomycoses Drug Production by Mechanism (2021-2026) & (K Dose)
Table 63. World Dermatomycoses Drug Production by Mechanism (2027-2032) & (K Dose)
Table 64. World Dermatomycoses Drug Production Value by Mechanism (2021-2026) & (USD Million)
Table 65. World Dermatomycoses Drug Production Value by Mechanism (2027-2032) & (USD Million)
Table 66. World Dermatomycoses Drug Average Price by Mechanism (2021-2026) & (US$/Dose)
Table 67. World Dermatomycoses Drug Average Price by Mechanism (2027-2032) & (US$/Dose)
Table 68. World Dermatomycoses Drug Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Dermatomycoses Drug Production by Application (2021-2026) & (K Dose)
Table 70. World Dermatomycoses Drug Production by Application (2027-2032) & (K Dose)
Table 71. World Dermatomycoses Drug Production Value by Application (2021-2026) & (USD Million)
Table 72. World Dermatomycoses Drug Production Value by Application (2027-2032) & (USD Million)
Table 73. World Dermatomycoses Drug Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Dermatomycoses Drug Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Biolab Farmaceutica Basic Information, Manufacturing Base and Competitors
Table 76. Biolab Farmaceutica Major Business
Table 77. Biolab Farmaceutica Dermatomycoses Drug Product and Services
Table 78. Biolab Farmaceutica Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Biolab Farmaceutica Recent Developments/Updates
Table 80. Biolab Farmaceutica Competitive Strengths & Weaknesses
Table 81. Blueberry Therapeutics Basic Information, Manufacturing Base and Competitors
Table 82. Blueberry Therapeutics Major Business
Table 83. Blueberry Therapeutics Dermatomycoses Drug Product and Services
Table 84. Blueberry Therapeutics Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Blueberry Therapeutics Recent Developments/Updates
Table 86. Blueberry Therapeutics Competitive Strengths & Weaknesses
Table 87. Daewoong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 88. Daewoong Pharmaceutical Major Business
Table 89. Daewoong Pharmaceutical Dermatomycoses Drug Product and Services
Table 90. Daewoong Pharmaceutical Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Daewoong Pharmaceutical Recent Developments/Updates
Table 92. Daewoong Pharmaceutical Competitive Strengths & Weaknesses
Table 93. Dermala Basic Information, Manufacturing Base and Competitors
Table 94. Dermala Major Business
Table 95. Dermala Dermatomycoses Drug Product and Services
Table 96. Dermala Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Dermala Recent Developments/Updates
Table 98. Dermala Competitive Strengths & Weaknesses
Table 99. Helix BioMedix Basic Information, Manufacturing Base and Competitors
Table 100. Helix BioMedix Major Business
Table 101. Helix BioMedix Dermatomycoses Drug Product and Services
Table 102. Helix BioMedix Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Helix BioMedix Recent Developments/Updates
Table 104. Helix BioMedix Competitive Strengths & Weaknesses
Table 105. Pelthos Basic Information, Manufacturing Base and Competitors
Table 106. Pelthos Major Business
Table 107. Pelthos Dermatomycoses Drug Product and Services
Table 108. Pelthos Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Pelthos Recent Developments/Updates
Table 110. Pelthos Competitive Strengths & Weaknesses
Table 111. Sol-Gel Technologies Basic Information, Manufacturing Base and Competitors
Table 112. Sol-Gel Technologies Major Business
Table 113. Sol-Gel Technologies Dermatomycoses Drug Product and Services
Table 114. Sol-Gel Technologies Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Sol-Gel Technologies Recent Developments/Updates
Table 116. Sol-Gel Technologies Competitive Strengths & Weaknesses
Table 117. Vyome Basic Information, Manufacturing Base and Competitors
Table 118. Vyome Major Business
Table 119. Vyome Dermatomycoses Drug Product and Services
Table 120. Vyome Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Vyome Recent Developments/Updates
Table 122. Vyome Competitive Strengths & Weaknesses
Table 123. Perrigo Basic Information, Manufacturing Base and Competitors
Table 124. Perrigo Major Business
Table 125. Perrigo Dermatomycoses Drug Product and Services
Table 126. Perrigo Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Perrigo Recent Developments/Updates
Table 128. Perrigo Competitive Strengths & Weaknesses
Table 129. Almirall Basic Information, Manufacturing Base and Competitors
Table 130. Almirall Major Business
Table 131. Almirall Dermatomycoses Drug Product and Services
Table 132. Almirall Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Almirall Recent Developments/Updates
Table 134. Almirall Competitive Strengths & Weaknesses
Table 135. Advacare Pharma Basic Information, Manufacturing Base and Competitors
Table 136. Advacare Pharma Major Business
Table 137. Advacare Pharma Dermatomycoses Drug Product and Services
Table 138. Advacare Pharma Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Advacare Pharma Recent Developments/Updates
Table 140. Advacare Pharma Competitive Strengths & Weaknesses
Table 141. Resources Sanjiu Basic Information, Manufacturing Base and Competitors
Table 142. Resources Sanjiu Major Business
Table 143. Resources Sanjiu Dermatomycoses Drug Product and Services
Table 144. Resources Sanjiu Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Resources Sanjiu Recent Developments/Updates
Table 146. Resources Sanjiu Competitive Strengths & Weaknesses
Table 147. Xiuzheng Basic Information, Manufacturing Base and Competitors
Table 148. Xiuzheng Major Business
Table 149. Xiuzheng Dermatomycoses Drug Product and Services
Table 150. Xiuzheng Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Xiuzheng Recent Developments/Updates
Table 152. Xiuzheng Competitive Strengths & Weaknesses
Table 153. Global Key Players of Dermatomycoses Drug Upstream (Raw Materials)
Table 154. Global Dermatomycoses Drug Typical Customers
Table 155. Dermatomycoses Drug Typical Distributors
Table 1. World Dermatomycoses Drug Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Dermatomycoses Drug Production Value by Region (2021-2026) & (USD Million)
Table 3. World Dermatomycoses Drug Production Value by Region (2027-2032) & (USD Million)
Table 4. World Dermatomycoses Drug Production Value Market Share by Region (2021-2026)
Table 5. World Dermatomycoses Drug Production Value Market Share by Region (2027-2032)
Table 6. World Dermatomycoses Drug Production by Region (2021-2026) & (K Dose)
Table 7. World Dermatomycoses Drug Production by Region (2027-2032) & (K Dose)
Table 8. World Dermatomycoses Drug Production Market Share by Region (2021-2026)
Table 9. World Dermatomycoses Drug Production Market Share by Region (2027-2032)
Table 10. World Dermatomycoses Drug Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Dermatomycoses Drug Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Dermatomycoses Drug Major Market Trends
Table 13. World Dermatomycoses Drug Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Dermatomycoses Drug Consumption by Region (2021-2026) & (K Dose)
Table 15. World Dermatomycoses Drug Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Dermatomycoses Drug Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Dermatomycoses Drug Producers in 2025
Table 18. World Dermatomycoses Drug Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Dermatomycoses Drug Producers in 2025
Table 20. World Dermatomycoses Drug Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Dermatomycoses Drug Company Evaluation Quadrant
Table 22. World Dermatomycoses Drug Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Dermatomycoses Drug Production Site of Key Manufacturer
Table 24. Dermatomycoses Drug Market: Company Product Type Footprint
Table 25. Dermatomycoses Drug Market: Company Product Application Footprint
Table 26. Dermatomycoses Drug Competitive Factors
Table 27. Dermatomycoses Drug New Entrant and Capacity Expansion Plans
Table 28. Dermatomycoses Drug Mergers & Acquisitions Activity
Table 29. United States VS China Dermatomycoses Drug Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Dermatomycoses Drug Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Dermatomycoses Drug Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Dermatomycoses Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Dermatomycoses Drug Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Dermatomycoses Drug Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Dermatomycoses Drug Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Dermatomycoses Drug Production Market Share (2021-2026)
Table 37. China Based Dermatomycoses Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Dermatomycoses Drug Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Dermatomycoses Drug Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Dermatomycoses Drug Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Dermatomycoses Drug Production Market Share (2021-2026)
Table 42. Rest of World Based Dermatomycoses Drug Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Dermatomycoses Drug Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Dermatomycoses Drug Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Dermatomycoses Drug Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Dermatomycoses Drug Production Market Share (2021-2026)
Table 47. World Dermatomycoses Drug Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Dermatomycoses Drug Production by Type (2021-2026) & (K Dose)
Table 49. World Dermatomycoses Drug Production by Type (2027-2032) & (K Dose)
Table 50. World Dermatomycoses Drug Production Value by Type (2021-2026) & (USD Million)
Table 51. World Dermatomycoses Drug Production Value by Type (2027-2032) & (USD Million)
Table 52. World Dermatomycoses Drug Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Dermatomycoses Drug Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Dermatomycoses Drug Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 55. World Dermatomycoses Drug Production by Dosage Form (2021-2026) & (K Dose)
Table 56. World Dermatomycoses Drug Production by Dosage Form (2027-2032) & (K Dose)
Table 57. World Dermatomycoses Drug Production Value by Dosage Form (2021-2026) & (USD Million)
Table 58. World Dermatomycoses Drug Production Value by Dosage Form (2027-2032) & (USD Million)
Table 59. World Dermatomycoses Drug Average Price by Dosage Form (2021-2026) & (US$/Dose)
Table 60. World Dermatomycoses Drug Average Price by Dosage Form (2027-2032) & (US$/Dose)
Table 61. World Dermatomycoses Drug Production Value by Mechanism, (USD Million), 2021 & 2025 & 2032
Table 62. World Dermatomycoses Drug Production by Mechanism (2021-2026) & (K Dose)
Table 63. World Dermatomycoses Drug Production by Mechanism (2027-2032) & (K Dose)
Table 64. World Dermatomycoses Drug Production Value by Mechanism (2021-2026) & (USD Million)
Table 65. World Dermatomycoses Drug Production Value by Mechanism (2027-2032) & (USD Million)
Table 66. World Dermatomycoses Drug Average Price by Mechanism (2021-2026) & (US$/Dose)
Table 67. World Dermatomycoses Drug Average Price by Mechanism (2027-2032) & (US$/Dose)
Table 68. World Dermatomycoses Drug Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Dermatomycoses Drug Production by Application (2021-2026) & (K Dose)
Table 70. World Dermatomycoses Drug Production by Application (2027-2032) & (K Dose)
Table 71. World Dermatomycoses Drug Production Value by Application (2021-2026) & (USD Million)
Table 72. World Dermatomycoses Drug Production Value by Application (2027-2032) & (USD Million)
Table 73. World Dermatomycoses Drug Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Dermatomycoses Drug Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Biolab Farmaceutica Basic Information, Manufacturing Base and Competitors
Table 76. Biolab Farmaceutica Major Business
Table 77. Biolab Farmaceutica Dermatomycoses Drug Product and Services
Table 78. Biolab Farmaceutica Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Biolab Farmaceutica Recent Developments/Updates
Table 80. Biolab Farmaceutica Competitive Strengths & Weaknesses
Table 81. Blueberry Therapeutics Basic Information, Manufacturing Base and Competitors
Table 82. Blueberry Therapeutics Major Business
Table 83. Blueberry Therapeutics Dermatomycoses Drug Product and Services
Table 84. Blueberry Therapeutics Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Blueberry Therapeutics Recent Developments/Updates
Table 86. Blueberry Therapeutics Competitive Strengths & Weaknesses
Table 87. Daewoong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 88. Daewoong Pharmaceutical Major Business
Table 89. Daewoong Pharmaceutical Dermatomycoses Drug Product and Services
Table 90. Daewoong Pharmaceutical Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Daewoong Pharmaceutical Recent Developments/Updates
Table 92. Daewoong Pharmaceutical Competitive Strengths & Weaknesses
Table 93. Dermala Basic Information, Manufacturing Base and Competitors
Table 94. Dermala Major Business
Table 95. Dermala Dermatomycoses Drug Product and Services
Table 96. Dermala Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Dermala Recent Developments/Updates
Table 98. Dermala Competitive Strengths & Weaknesses
Table 99. Helix BioMedix Basic Information, Manufacturing Base and Competitors
Table 100. Helix BioMedix Major Business
Table 101. Helix BioMedix Dermatomycoses Drug Product and Services
Table 102. Helix BioMedix Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Helix BioMedix Recent Developments/Updates
Table 104. Helix BioMedix Competitive Strengths & Weaknesses
Table 105. Pelthos Basic Information, Manufacturing Base and Competitors
Table 106. Pelthos Major Business
Table 107. Pelthos Dermatomycoses Drug Product and Services
Table 108. Pelthos Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Pelthos Recent Developments/Updates
Table 110. Pelthos Competitive Strengths & Weaknesses
Table 111. Sol-Gel Technologies Basic Information, Manufacturing Base and Competitors
Table 112. Sol-Gel Technologies Major Business
Table 113. Sol-Gel Technologies Dermatomycoses Drug Product and Services
Table 114. Sol-Gel Technologies Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Sol-Gel Technologies Recent Developments/Updates
Table 116. Sol-Gel Technologies Competitive Strengths & Weaknesses
Table 117. Vyome Basic Information, Manufacturing Base and Competitors
Table 118. Vyome Major Business
Table 119. Vyome Dermatomycoses Drug Product and Services
Table 120. Vyome Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Vyome Recent Developments/Updates
Table 122. Vyome Competitive Strengths & Weaknesses
Table 123. Perrigo Basic Information, Manufacturing Base and Competitors
Table 124. Perrigo Major Business
Table 125. Perrigo Dermatomycoses Drug Product and Services
Table 126. Perrigo Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Perrigo Recent Developments/Updates
Table 128. Perrigo Competitive Strengths & Weaknesses
Table 129. Almirall Basic Information, Manufacturing Base and Competitors
Table 130. Almirall Major Business
Table 131. Almirall Dermatomycoses Drug Product and Services
Table 132. Almirall Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Almirall Recent Developments/Updates
Table 134. Almirall Competitive Strengths & Weaknesses
Table 135. Advacare Pharma Basic Information, Manufacturing Base and Competitors
Table 136. Advacare Pharma Major Business
Table 137. Advacare Pharma Dermatomycoses Drug Product and Services
Table 138. Advacare Pharma Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Advacare Pharma Recent Developments/Updates
Table 140. Advacare Pharma Competitive Strengths & Weaknesses
Table 141. Resources Sanjiu Basic Information, Manufacturing Base and Competitors
Table 142. Resources Sanjiu Major Business
Table 143. Resources Sanjiu Dermatomycoses Drug Product and Services
Table 144. Resources Sanjiu Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Resources Sanjiu Recent Developments/Updates
Table 146. Resources Sanjiu Competitive Strengths & Weaknesses
Table 147. Xiuzheng Basic Information, Manufacturing Base and Competitors
Table 148. Xiuzheng Major Business
Table 149. Xiuzheng Dermatomycoses Drug Product and Services
Table 150. Xiuzheng Dermatomycoses Drug Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Xiuzheng Recent Developments/Updates
Table 152. Xiuzheng Competitive Strengths & Weaknesses
Table 153. Global Key Players of Dermatomycoses Drug Upstream (Raw Materials)
Table 154. Global Dermatomycoses Drug Typical Customers
Table 155. Dermatomycoses Drug Typical Distributors
LIST OF FIGURES
Figure 1. Dermatomycoses Drug Picture
Figure 2. World Dermatomycoses Drug Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Dermatomycoses Drug Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Dermatomycoses Drug Production (2021-2032) & (K Dose)
Figure 5. World Dermatomycoses Drug Average Price (2021-2032) & (US$/Dose)
Figure 6. World Dermatomycoses Drug Production Value Market Share by Region (2021-2032)
Figure 7. World Dermatomycoses Drug Production Market Share by Region (2021-2032)
Figure 8. North America Dermatomycoses Drug Production (2021-2032) & (K Dose)
Figure 9. Europe Dermatomycoses Drug Production (2021-2032) & (K Dose)
Figure 10. Asia Dermatomycoses Drug Production (2021-2032) & (K Dose)
Figure 11. Latin America Dermatomycoses Drug Production (2021-2032) & (K Dose)
Figure 12. Middle East Dermatomycoses Drug Production (2021-2032) & (K Dose)
Figure 13. Dermatomycoses Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 16. World Dermatomycoses Drug Consumption Market Share by Region (2021-2032)
Figure 17. United States Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 18. China Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 19. Europe Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 20. Japan Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 21. South Korea Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 22. ASEAN Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 23. India Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 24. Producer Shipments of Dermatomycoses Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Dermatomycoses Drug Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Dermatomycoses Drug Markets in 2025
Figure 27. United States VS China: Dermatomycoses Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Dermatomycoses Drug Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Dermatomycoses Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers Dermatomycoses Drug Production Market Share 2025
Figure 31. China Based Manufacturers Dermatomycoses Drug Production Market Share 2025
Figure 32. Rest of World Based Manufacturers Dermatomycoses Drug Production Market Share 2025
Figure 33. World Dermatomycoses Drug Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World Dermatomycoses Drug Production Value Market Share by Type in 2025
Figure 35. Topical Drug
Figure 36. Oral Drug
Figure 37. World Dermatomycoses Drug Production Market Share by Type (2021-2032)
Figure 38. World Dermatomycoses Drug Production Value Market Share by Type (2021-2032)
Figure 39. World Dermatomycoses Drug Average Price by Type (2021-2032) & (US$/Dose)
Figure 40. World Dermatomycoses Drug Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 41. World Dermatomycoses Drug Production Value Market Share by Dosage Form in 2025
Figure 42. Cream
Figure 43. Solution
Figure 44. Lacquer
Figure 45. Powder
Figure 46.Tablet
Figure 47. World Dermatomycoses Drug Production Market Share by Dosage Form (2021-2032)
Figure 48. World Dermatomycoses Drug Production Value Market Share by Dosage Form (2021-2032)
Figure 49. World Dermatomycoses Drug Average Price by Dosage Form (2021-2032) & (US$/Dose)
Figure 50. World Dermatomycoses Drug Production Value by Mechanism, (USD Million), 2021 & 2025 & 2032
Figure 51. World Dermatomycoses Drug Production Value Market Share by Mechanism in 2025
Figure 52. Ergosterol Synthesis Inhibitor
Figure 53. Cell Membrane Disruptor
Figure 54. Keratinization Promoter
Figure 55. World Dermatomycoses Drug Production Market Share by Mechanism (2021-2032)
Figure 56. World Dermatomycoses Drug Production Value Market Share by Mechanism (2021-2032)
Figure 57. World Dermatomycoses Drug Average Price by Mechanism (2021-2032) & (US$/Dose)
Figure 58. World Dermatomycoses Drug Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 59. World Dermatomycoses Drug Production Value Market Share by Application in 2025
Figure 60. Hospital
Figure 61. Retail Pharmacy
Figure 62. Online Pharmacy
Figure 63. World Dermatomycoses Drug Production Market Share by Application (2021-2032)
Figure 64. World Dermatomycoses Drug Production Value Market Share by Application (2021-2032)
Figure 65. World Dermatomycoses Drug Average Price by Application (2021-2032) & (US$/Dose)
Figure 66. Dermatomycoses Drug Industry Chain
Figure 67. Dermatomycoses Drug Procurement Model
Figure 68. Dermatomycoses Drug Sales Model
Figure 69. Dermatomycoses Drug Sales Channels, Direct Sales, and Distribution
Figure 70. Methodology
Figure 71. Research Process and Data Source
Figure 1. Dermatomycoses Drug Picture
Figure 2. World Dermatomycoses Drug Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Dermatomycoses Drug Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Dermatomycoses Drug Production (2021-2032) & (K Dose)
Figure 5. World Dermatomycoses Drug Average Price (2021-2032) & (US$/Dose)
Figure 6. World Dermatomycoses Drug Production Value Market Share by Region (2021-2032)
Figure 7. World Dermatomycoses Drug Production Market Share by Region (2021-2032)
Figure 8. North America Dermatomycoses Drug Production (2021-2032) & (K Dose)
Figure 9. Europe Dermatomycoses Drug Production (2021-2032) & (K Dose)
Figure 10. Asia Dermatomycoses Drug Production (2021-2032) & (K Dose)
Figure 11. Latin America Dermatomycoses Drug Production (2021-2032) & (K Dose)
Figure 12. Middle East Dermatomycoses Drug Production (2021-2032) & (K Dose)
Figure 13. Dermatomycoses Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 16. World Dermatomycoses Drug Consumption Market Share by Region (2021-2032)
Figure 17. United States Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 18. China Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 19. Europe Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 20. Japan Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 21. South Korea Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 22. ASEAN Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 23. India Dermatomycoses Drug Consumption (2021-2032) & (K Dose)
Figure 24. Producer Shipments of Dermatomycoses Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Dermatomycoses Drug Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Dermatomycoses Drug Markets in 2025
Figure 27. United States VS China: Dermatomycoses Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Dermatomycoses Drug Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Dermatomycoses Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers Dermatomycoses Drug Production Market Share 2025
Figure 31. China Based Manufacturers Dermatomycoses Drug Production Market Share 2025
Figure 32. Rest of World Based Manufacturers Dermatomycoses Drug Production Market Share 2025
Figure 33. World Dermatomycoses Drug Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World Dermatomycoses Drug Production Value Market Share by Type in 2025
Figure 35. Topical Drug
Figure 36. Oral Drug
Figure 37. World Dermatomycoses Drug Production Market Share by Type (2021-2032)
Figure 38. World Dermatomycoses Drug Production Value Market Share by Type (2021-2032)
Figure 39. World Dermatomycoses Drug Average Price by Type (2021-2032) & (US$/Dose)
Figure 40. World Dermatomycoses Drug Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 41. World Dermatomycoses Drug Production Value Market Share by Dosage Form in 2025
Figure 42. Cream
Figure 43. Solution
Figure 44. Lacquer
Figure 45. Powder
Figure 46.Tablet
Figure 47. World Dermatomycoses Drug Production Market Share by Dosage Form (2021-2032)
Figure 48. World Dermatomycoses Drug Production Value Market Share by Dosage Form (2021-2032)
Figure 49. World Dermatomycoses Drug Average Price by Dosage Form (2021-2032) & (US$/Dose)
Figure 50. World Dermatomycoses Drug Production Value by Mechanism, (USD Million), 2021 & 2025 & 2032
Figure 51. World Dermatomycoses Drug Production Value Market Share by Mechanism in 2025
Figure 52. Ergosterol Synthesis Inhibitor
Figure 53. Cell Membrane Disruptor
Figure 54. Keratinization Promoter
Figure 55. World Dermatomycoses Drug Production Market Share by Mechanism (2021-2032)
Figure 56. World Dermatomycoses Drug Production Value Market Share by Mechanism (2021-2032)
Figure 57. World Dermatomycoses Drug Average Price by Mechanism (2021-2032) & (US$/Dose)
Figure 58. World Dermatomycoses Drug Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 59. World Dermatomycoses Drug Production Value Market Share by Application in 2025
Figure 60. Hospital
Figure 61. Retail Pharmacy
Figure 62. Online Pharmacy
Figure 63. World Dermatomycoses Drug Production Market Share by Application (2021-2032)
Figure 64. World Dermatomycoses Drug Production Value Market Share by Application (2021-2032)
Figure 65. World Dermatomycoses Drug Average Price by Application (2021-2032) & (US$/Dose)
Figure 66. Dermatomycoses Drug Industry Chain
Figure 67. Dermatomycoses Drug Procurement Model
Figure 68. Dermatomycoses Drug Sales Model
Figure 69. Dermatomycoses Drug Sales Channels, Direct Sales, and Distribution
Figure 70. Methodology
Figure 71. Research Process and Data Source
